Growth Metrics

Boston Scientific (BSX) Net Cash Flow (2016 - 2026)

Boston Scientific's Net Cash Flow history spans 18 years, with the latest figure at -$503.0 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 283.58% to -$503.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $722.0 million, a 144.79% increase, with the full-year FY2025 number at $1.5 billion, up 442.24% from a year prior.
  • Net Cash Flow hit -$503.0 million in Q1 2026 for Boston Scientific, down from $668.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for BSX hit a ceiling of $1.4 billion in Q1 2024 and a floor of -$2.0 billion in Q4 2024.
  • Historically, Net Cash Flow has averaged -$31.8 million across 5 years, with a median of -$66.0 million in 2022.
  • Biggest five-year swings in Net Cash Flow: surged 6844.44% in 2022 and later plummeted 2411.11% in 2024.
  • Tracing BSX's Net Cash Flow over 5 years: stood at $625.0 million in 2022, then crashed by 112.96% to -$81.0 million in 2023, then plummeted by 2411.11% to -$2.0 billion in 2024, then soared by 132.84% to $668.0 million in 2025, then crashed by 175.3% to -$503.0 million in 2026.
  • Business Quant data shows Net Cash Flow for BSX at -$503.0 million in Q1 2026, $668.0 million in Q4 2025, and $737.0 million in Q3 2025.